Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year.
Mantle cell lymphoma (MCL) is an infrequent subtype of non-Hodgkin's lymphoma (NHL) and represents between 4-8% of adult lymphomas. Recently an increase in its incidence to 1-2 cases/100,000 inhabitants/year has been observed. The first line of treatment is based on chemoimmunotherapy and depends on age and the initial stage at diagnosis. There are no second line or successive treatments. There are currently several drugs available that provide acceptable results.
Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain.
Carmen
C
Herrero-Vicent
Pathological Anatomy Department, Instituto Valenciano de Oncología, Valencia, Spain.
Isidro
I
Machado
Pathological Anatomy Department, Instituto Valenciano de Oncología, Valencia, Spain.
Carmen
C
Illueca
Haematology Unit, Instituto Valenciano de Oncología, Valencia, Spain.
Amparo
A
Avaria
Haematology Unit, Instituto Valenciano de Oncología, Valencia, Spain.
Claudia
C
Salazar
Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain.
Abraham
A
Hernandez
Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain.
Sergio
S
Sandiego
Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain.
Javier
J
Lavernia
chemoimmunotherapy; mantle cell lymphoma; new drugs; prognostic factors